trimethobenzamide has been researched along with Parkinson Disease in 4 studies
trimethobenzamide: major descriptor (64-84); on-line search BENZAMIDES (64-84); Index Medicus search TRIMETHOBENZAMIDE (64-84); RN given refers to parent cpd
trimethobenzamide : The amide obtained by formal condensation of 3,4,5-trihydroxybenzoic acid with 4-[2-(N,N-dimethylamino)ethoxy]benzylamine. It is used to prevent nausea and vomitting in humans.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Incidence of nausea and/or vomiting on Day 1 of apomorphine initiation (primary endpoint) was not significantly different between trimethobenzamide and placebo." | 9.19 | Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. ( Clinch, T; Hauser, RA; Isaacson, S, 2014) |
| "Incidence of nausea and/or vomiting on Day 1 of apomorphine initiation (primary endpoint) was not significantly different between trimethobenzamide and placebo." | 5.19 | Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. ( Clinch, T; Hauser, RA; Isaacson, S, 2014) |
| " Oral trimethobenzamide was used to prevent apomorphine-induced nausea." | 5.08 | Intranasal apomorphine rescue therapy for parkinsonian "off" periods. ( Ahlskog, JE; Dewey, RB; Maraganore, DM; Matsumoto, JY, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hauser, RA | 1 |
| Isaacson, S | 1 |
| Clinch, T | 1 |
| Dewey, RB | 3 |
| Maraganore, DM | 2 |
| Ahlskog, JE | 2 |
| Matsumoto, JY | 2 |
3 trials available for trimethobenzamide and Parkinson Disease
| Article | Year |
|---|---|
Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiemetics; Apomorphine; Benzamides; Dopamine | 2014 |
Intranasal apomorphine rescue therapy for parkinsonian "off" periods.
Topics: Administration, Intranasal; Antiemetics; Antiparkinson Agents; Apomorphine; Benzamides; Carbidopa; D | 1996 |
A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease.
Topics: Administration, Intranasal; Aerosols; Aged; Antiemetics; Antiparkinson Agents; Apomorphine; Benzamid | 1998 |
1 other study available for trimethobenzamide and Parkinson Disease
| Article | Year |
|---|---|
10 questions about using apomorphine for Parkinson disease.
Topics: Antiemetics; Antiparkinson Agents; Apomorphine; Benzamides; Humans; Injections, Intravenous; Parkins | 2005 |